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Abstract
Background: The androgen insensitivity syndrome may cause developmental failure of normal male external
genitalia in individuals with 46,XY karyotype. It results from the diminished or absent biological action of
androgens, which is mediated by the androgen receptor in both embryo and secondary sex development.
Mutations in the androgen receptor gene, located on the X chromosome, are responsible for the disease. Almost
70% of 46,XY affected individuals inherited mutations from their carrier mothers.
Findings: Molecular abnormalities in the androgen receptor gene in individuals of a Brazilian family with clinical
features of severe forms of partial androgen insensitivity syndrome were evaluated. Seven members (five 46,XY
females and two healthy mothers) of the family were included in the investigation. The coding exons and exon-
intron junctions of androgen receptor gene were sequenced. Five 46,XY members of the family have been found to
be hemizygous for the c.3015C>T nucleotide change in exon 7 of the androgen receptor gene, whereas the two 46,
XX mothers were heterozygote carriers. This nucleotide substitution leads to the p.L830F mutation in the androgen
receptor.
Conclusions: The novel p.L830F mutation is responsible for grades 5 and 6 of partial androgen insensitivity
syndrome in two generations of a Brazilian family.
Findings
The androgen insensitivity syndrome (AIS, OMIN
#300068) is a recessive disorder linked to the X chromo-
some. It may result in the failure of external genitalia
masculinization in individuals with 46,XY karyotype and
normal androgen production and metabolism [1,2].
There is a wide range of clinical manifestation, therefore
the syndrome can be divided in three subgroups accord-
ing the degree of undermasculinization: 1) mild AIS
(MAIS) that is characterized by gynecomastia and infer-
tility in phenotypically male individuals; 2) partial AIS
(PAIS) that may present with predominantly male devel-
opment or ambiguous genitalia (AG) or even with pre-
dominantly female external genitalia with clitoromegaly
and/or posterior labial fusion and breast and pubic hair
development; 3) complete AIS (CAIS) resulting in
female external genitalia, sparse to absent pubic and axi-
lary hair and normal breast development [2-6]. Due to
significant differences generally found among clinical
manifestation features in PAIS, some authors assigned
grades ranging from 1 to 6 to describe patients that pre-
sented with different phenotypes varying from male gen-
italia and infertility to female genitalia with pubic and
underarm hair [2,5,6].
The androgen activity is mediated by the androgen
receptor (AR), a member of nuclear receptor family,
which is encoded by the androgen receptor gene (AR).
The gene is located on the X-chromosome at Xq11 - 12
and is formed by eight exons and seven introns that
spans ~ 90 kb of DNA [7,8]. The AR protein contains
approximately 919 amino acid residues, but this number
is variable due to the existence of both polyglutamine
and polyglycine stretches in the amino terminal region
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among individuals [9,10]. Like other members of the
nuclear receptor superfamily, the AR contains four dif-
ferent functional domains: an amino-terminal domain
encoded by exon 1, which is a non-conserved region
involved in transcriptional activation of target genes
[11]; a central DNA-binding domain (DBD) encoded by
exons 2 and 3, which contains two zinc finger motifs
[12,13]; a hinge region containing the nuclear targeting
signal [14] and a C-terminal ligand binding domain
(LBD) encoded by exons 4-8 that also encompasses sub-
domains involved in dimerization and transcriptional
activation processes [15,16].
Mutations in the AR gene lead to AIS [5,17,18]. Such
mutations are found differently distributed throughout
the gene sequence [[19], website: http://www.mcgill.ca/
androgendb]. Almost 70% of 46,XY affected individuals
inherited mutations from their carrier mothers [20]. As
discussed by Boehmer et al. [21] the identification of a
specific AR mutation and its residual androgen action
always provide more precise diagnosis and/or prognosis,
which might contribute to the decision for sex assign-
ment of 46,XY individuals with AIS and facilitate genetic
counseling of carrier females. In addition, due to clinical
and genetic heterogeneity of the condition, studies
describing novel mutations in AIS provide important
information for the function of a specific amino acid
residue.
Therefore, the purpose of this study was to identify
the AR gene mutation in a Brazilian family with five
patients presenting PAIS corresponding to grades 5 and
6. The role of the novel p.L830F missense mutation in
the AR within LBD is discussed by comparing structural
characteristics of both normal and mutant proteins.
Ethics and Consents
This study was approved by the Ethics Committee from
Universidade Estadual de Campinas (São Paulo, Brasil)
and informed consents were obtained from patients and
relatives; informed consents from individuals III-10 and
IV-1 were obtained separately for the publication of
Figures 1B and 1C.
Methods
Seven individuals from two generations of a family
(Figure 1A) were included in this study. The index
case (Figure 1A, III-10), an 18-year-old girl, was
referred to us due to primary amenorrhea with sponta-
neous telarche and pubarche and palpable gonads in
the inguinal region. She was born at term after an
uneventful pregnancy by cesarian section with a birth
weight of 3,330 g and height of 48 cm. Bilateral ingu-
inal gonads were detected at birth. She was followed
up over a period of eight months when assignment of
female gender was decided; corrective procedure for
inguinal gonads was planned but did not occur. On
physical examination, she had typical female external
genitalia, with only a slight posterior fusion of labio-
scrotal folds. Palpable gonads were found bilaterally in
the inguinal region with volumes of 15 cm
3, whereas
pubertal development had reached Tanner stage B4P5
(Figure 1B). The uterus was absent under pelvic sono-
grams. Hormonal evaluation revealed normal FSH
(5.4 mIU/mL; normal range (NR): 1.5 - 12.4 mIU/mL)
and elevated levels of both LH (21.2 mIU/mL; NR: 1.7
- 8.6 mIU/mL) and total testosterone (>15 ng/mL; NR:
2.86 - 8.1 ng/mL); her karyotype was 46,XY. The bone
mineral density test revealed femoral osteopenia and
lumbar osteoporosis. Gonadectomy was performed a
few months later and histological analysis revealed
bilateral testes with no evidence of malignancy. She
was subsequently referred to other services to perform
vaginoplasty and to start hormone replacement therapy
with estrogens and treatment of osteopenia/osteoporo-
sis. Her parents were first cousins, and there was a
positive family history with individuals presenting simi-
lar features: three nieces with palpable gonads and an
older sister.
A 24-year-old sister (Figure 1A, III-3) that had inguinal
gonads corrected in the first year of life, referred with pri-
mary amenorrhea, spontaneous breast development. On
physical examination, pubertal development had reached
Tanner stage B5P4. She was oriented to perform bilateral
gonadectomy, vaginoplasty and hormone replacement.
A3 - y e a ro l dn i e c e( F i g u r e1 ,I V - 1 )w a st h eo n l yc h i l d
of unrelated parents. She was born at term by normal
Figure 1 Inheritance of androgen insensitivity syndrome in the
family. Family pedigree (A). Female genitalia with palpable gonads
in the index case III-10 (B) and her niece IV-1 (C).
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of 2,800 g, and bilateral inguinal gonads were detected
at birth. On physical examination, she had typical pre-
pubertal female genitalia and bilaterally palpable gonads
were found in the inguinal region (Figure 1C). Her kar-
yotype was 46,XY. After receiving all relevant informa-
tion about risks and benefits of early versus late
gonadectomy, her parents decided to delay surgery in
order to allow spontaneous puberty. The girl was then
referred to the pediatric endocrinology service for follow
up.
A 1.5-year-old niece (Figure 1A, IV-2) was also the
first child of unrelated parents. She was born at term by
normal delivery after an uneventful pregnancy with
birth weight of 2,650 g, and palpable gonads in the ingu-
inal region were detected at birth. On physical examina-
tion, she had typical female external genitalia, with only
a slight posterior fusion of labioscrotal folds. Her karyo-
type was 46,XY. Her parents decided to delay surgery
until after puberty and the girl was referred to the
pediatric endocrinology service for follow up. Her sister
(Figure 1A, IV-3) was brought to us when she was 3
month old due to palpable gonads in the inguinal
region, which had been detected at birth. She was born
at term after an uneventful pregnancy by normal deliv-
e r yw i t hab i r t hw e i g h to f3 , 1 8 0ga n dl e n g t h4 9 . 5c m .
On physical examination, she had typical female exter-
nal genitalia and both gonads were palpable in the ingu-
inal regions. Her karyotype was 46,XY.
Samples of genomic DNA were obtained from periph-
eral blood by proteinase K/phenol extraction method
[22]. Molecular analysis was performed by amplifying
the eight exons of AR gene using the polymerase chain
reaction (PCR) followed by sequencing the fragments
using Big Dye
® Terminator Cycle Sequencing Kit V3.1
Ready Reaction (ABI PRISM/PE Biosystems). The
sequences obtained in an ABI 3700 Sequencer (ABI
PRISM/PE Biosystems) were compared with the normal
sequence of the gene (ENSEMBL-ENSG00000169083)
using Chromas (reduced version - free software) and
GeneRunner v.3.05 (free software) or CLC Sequence
Viewer v.6.2 (free software).
The model of human AR mutant protein was built
using the resolved 3-D structure of human AR (PDB
accession # 2AM9) as template. Molecular modeling
was performed using MODELLER web-server program.
The model images were examined and edited using
PyMOL
® program and Millennium STING (CNPTIA-
Embrapa, Brasil). The human AR sequence was com-
pared with the corresponding mammalian proteins
sequences in the ClustalW http://www.genome.jp/tools/
clustalw/.
Results
Upon sequencing exons 2 to 8 of the AR gene, a novel
c.3015C>T nucleotide change in exon 7 was identified
in five 46,XY female hemizygote individuals and also in
two heterozygote carrier mothers (Figure 2A). This
nucleotide change cause the putative replacement of a
leucine by a phenylalanine residue at codon 830
(p.L830F).
Exon 1 sequencing showed 21 and 20 repeats of each
CAG (SNP # rs5902610) and GGC, respectively, for the
affected individuals. In addition, three GGT codons pre-
ceded the GGC stretch instead the two normally found
in the AR gene. Besides the mutation, the heterozygote
carrier mothers (Figure 1A: III-4, III-8) were also het-
erozygous for the c.639G>A (SNP # rs6152) and c.2319-
Figure 2 Nucleotide change leading to p.L830F mutation and protein residue conservation. The c.3015C>T nucleotide change in exon 7
is illustrated in the AR gene partial electropherogram: (A) normal sequence; (B) hemizygous mutant sequence from the index case III-10. (C) Part
of multiple sequence alignment for the human AR protein and other mammalian AR proteins; the residue 830 is depicted in red for all species.
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and intron 5, respectively.
Multiple alignments comparing the human AR protein
sequence to other mammalian AR proteins indicated the
L 8 3 0a sah i g h l yc o n s e r v e dr e s i d u e( F i g u r e2 B ) .T h e
structural analysis by modeling normal and mutant pro-
teins (Figure 3A) revealed that the discrepancy of the
mutant F830 compared to the normal L830 resides
mainly in the abolishment of a hydrophobic interaction
with F813 residue and in the creation of two different
internal hydrophobic interactions with both G724 and
N727 residues (Figure 3B and 3C). Since the interaction
between L830 and F813 residues was suppressed by the
mutation, several interactions involving F813 and other
amino acids have also been disrupted (Figure 3D). It
was also observed that the distance between F830 and
either G724 or N727 residues has shortened to 2.94 Å
(Figure 3B).
Discussion
We report here the novel p.L830F mutation in the hor-
mone binding region of the androgen receptor that is
responsible for partial androgen insensitivity syndrome
in a Brazilian family. Five patients in two generations
carry the mutation. The index case (Figure 1A, III-10)
and her niece (Figure 1A, IV-2) showed clinical and
laboratorial data compatible with PAIS grade 5, since
they had female external genitalia with a slight posterior
fusion of labioscrotal folds and palpable gonads [2,6].
Whereas, her older sister (Figure 1, III-3) and two nieces
(Figure 1, IV-1 and IV-3) presented with typical female
external genitalia and palpable gonads [2,6], which clas-
sify them as PAIS grade 6. The presence of pubic hair
was observed in the two sisters; however, it could not
be verified in the nieces because they have not reached
puberty yet.
In addition to the mutation, all patients presented 21
and 20 repeats for polyglutamine and polyglycine
stretches, respectively, both within the range described
as normal [23]. The 46,XX heterozygote mothers (Figure
1: III-4, III-8) were also heterozygous for both c.639G>A
(SNP # rs6152) and c.2319-78G>T (SNP # rs1337076)
polymorphisms. Since A and T nucleotides are, respec-
tively, rare and very rare alleles (NCBI SNP database) in
Figure 3 Modeling for normal and mutant AR proteins. (A) Comparison of normal and mutant human AR protein models at residue 830;
normal leucine is denoted in green and phenylalanine in red. (B) Distances in Ångström (Å) for contacts for the F830 mutant residue estimated
using PyMOL software: hydrogen bonds are shown in brown and hydrophobic interactions in purple. (C - F) Internal contacts provided by the
analysis with BlueStar STING software. The native residue L830 (C) forms energetic hydrogen bonds with F826, F827, N833 and Y834 and a
hydrophobic interaction with F813, whereas the mutant residue F830 (D) suppresses the interaction with F813 and introduces two additional
hydrophobic interactions with G724 and N727. Effects upon internal contacts for F813 residue: in the normal protein, the F813 residue presents
hydrophobic interaction with F827 and Y834 (E), whereas in the mutant protein those interactions are lost (F).
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nal inherited allele also corresponds to a rare AR allele.
Missense mutations in AR protein may cause a spec-
trum of phenotypes that include complete androgen
insensitivity in 46,XY individuals with female genitalia
and partial androgen insensitivity in 46,XY individuals
with male phenotype, except for perineoscrotal hypospa-
dias, gynecomastia and/or infertility [19]. The phenotype
variability appears to reflect the degree to which ligand-
binding and receptor functions are disrupted by differ-
ent substitutions [24]. In addition, genetic background
also influences the resulting phenotype since a same
mutation may cause different forms of AIS within a
family [3,25]. The most frequent are missense mutations
that are found within two important areas of the recep-
tor protein: DBD and LDB domains [8]. The importance
o ft h eL 8 3 0r e s i d u ef o rt h eA Ra c t i v i t ym a yb ei n f e r r e d
by p.L830V described before in a patient with CAIS
[26]. In addition, the neighboring codon 831 was target
for several missense mutations such as p.R831L and
p.R831Q also causing CAIS [27,28]. Therefore, muta-
tions in codon 830 may severely disturb the functional
activity of LBD in which two hot spots for mutations
have been identified [24].
X-ray crystallographic studies showed that the three-
dimensional structure of the AR-LBD encompasses 12
a-helices [29]. In the normal molecule these a-helices
undergo conformational changes in response to ligand-
binding resulting in the assembly of the AF-2 domain.
According to AR structure, the amino acid L830 is
located within the a-helix 9 that comprises residues
825-847. This region has been proposed as part of an
allosteric regulatory site termed binding function 3 (BF-
3) where ligand interactions exert indirect effects on
AF-2 to modulate co-regulator binding [30]. Mutations
in BF-3 have demonstrated to diminish AR activity and
they can be related with different phenotypes [30].
When the leucine is replaced by the phenylalanine in
codon 830 the hydrophobic character of the residue is
maintained, but the change of a high hydrophobic leucine
to a less hydrophobic phenylalanine might affect the tran-
scriptional activity as described for p.F826L mutation [31].
Considering the structural analysis for p.L830F, it can be
proposed that the suppression of a hydrophobic interac-
tion with residue F813 might destabilize the interaction
between alpha-helices 8 and 9 which forms an important
hydrophobic core to keep the AR binding capacity [32].
Conversely, the mutant residue established novel contacts
with amino acids G724 and N727 that are located between
alpha-helices 3 and 4, both residues are highly conserved
and critical for ligand binding [17,31,33]. The creation of
such hydrophobic contacts suggests that the p.L830F sub-
stitution would reduce the mobility of the region involving
alpha-helix 9 and the region between alpha-helices 3 and
4. Also, those new interactions brought F830 and each
G724 and N727 amino acids more close such as surface
contacts of F830-G724 and F830-N727 enhanced leading
to stronger interactions between the loop region located in
the middle of alpha-helices 3 and 4 and alpha-helix 9.
Those interactions give the region less flexibility than that
necessary to allow properly co-factor assembly of AF-2
domain [34]. In conclusion, the decrease on the hydropho-
bicity of residue 830 and changes in the internal contacts
caused by p.L830F mutation are probably responsible for a
very low androgen receptor activity which might correlate
with the severe PAIS phenotype observed for the patients.
Similarly to other mutations described in this domain as
causing different phenotypes within a family [3,25], p.
L830F produced different PAIS grades in the family
described here indicating an influence of genetic back-
ground on its effect.
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